These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 24269558

  • 1. PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases.
    Lin Y, Huang G, Jamison S, Li J, Harding HP, Ron D, Lin W.
    Am J Pathol; 2014 Feb; 184(2):507-19. PubMed ID: 24269558
    [Abstract] [Full Text] [Related]

  • 2. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress.
    Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B.
    Brain; 2006 May; 129(Pt 5):1306-18. PubMed ID: 16504972
    [Abstract] [Full Text] [Related]

  • 3. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis.
    Lin W, Lin Y, Li J, Fenstermaker AG, Way SW, Clayton B, Jamison S, Harding HP, Ron D, Popko B.
    J Neurosci; 2013 Apr 03; 33(14):5980-91. PubMed ID: 23554479
    [Abstract] [Full Text] [Related]

  • 4. Oligodendrocyte-specific ATF4 inactivation does not influence the development of EAE.
    Yue Y, Stanojlovic M, Lin Y, Karsenty G, Lin W.
    J Neuroinflammation; 2019 Feb 01; 16(1):23. PubMed ID: 30709400
    [Abstract] [Full Text] [Related]

  • 5. Genetic inactivation of PERK signaling in mouse oligodendrocytes: normal developmental myelination with increased susceptibility to inflammatory demyelination.
    Hussien Y, Cavener DR, Popko B.
    Glia; 2014 May 01; 62(5):680-91. PubMed ID: 24481666
    [Abstract] [Full Text] [Related]

  • 6. Activating transcription factor 6α deficiency exacerbates oligodendrocyte death and myelin damage in immune-mediated demyelinating diseases.
    Stone S, Wu S, Jamison S, Durose W, Pallais JP, Lin W.
    Glia; 2018 Jul 01; 66(7):1331-1345. PubMed ID: 29436030
    [Abstract] [Full Text] [Related]

  • 7. Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment.
    Chen Y, Kunjamma RB, Weiner M, Chan JR, Popko B.
    Elife; 2021 Mar 23; 10():. PubMed ID: 33752802
    [Abstract] [Full Text] [Related]

  • 8. NF-κB Activation Accounts for the Cytoprotective Effects of PERK Activation on Oligodendrocytes during EAE.
    Lei Z, Yue Y, Stone S, Wu S, Lin W.
    J Neurosci; 2020 Aug 12; 40(33):6444-6456. PubMed ID: 32661025
    [Abstract] [Full Text] [Related]

  • 9. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage.
    Lin W, Bailey SL, Ho H, Harding HP, Ron D, Miller SD, Popko B.
    J Clin Invest; 2007 Feb 12; 117(2):448-56. PubMed ID: 17273557
    [Abstract] [Full Text] [Related]

  • 10. NF-κB Activation Protects Oligodendrocytes against Inflammation.
    Stone S, Jamison S, Yue Y, Durose W, Schmidt-Ullrich R, Lin W.
    J Neurosci; 2017 Sep 20; 37(38):9332-9344. PubMed ID: 28842413
    [Abstract] [Full Text] [Related]

  • 11. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
    Qin J, Sikkema AH, van der Bij K, de Jonge JC, Klappe K, Nies V, Jonker JW, Kok JW, Hoekstra D, Baron W.
    J Neurosci; 2017 Oct 11; 37(41):9925-9938. PubMed ID: 28899916
    [Abstract] [Full Text] [Related]

  • 12. Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma.
    Lin W, Harding HP, Ron D, Popko B.
    J Cell Biol; 2005 May 23; 169(4):603-12. PubMed ID: 15911877
    [Abstract] [Full Text] [Related]

  • 13. Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.
    Khalaj AJ, Hasselmann J, Augello C, Moore S, Tiwari-Woodruff SK.
    J Steroid Biochem Mol Biol; 2016 Jun 23; 160():43-52. PubMed ID: 26776441
    [Abstract] [Full Text] [Related]

  • 14. Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders.
    Mausner-Fainberg K, Benhamou M, Golan M, Kimelman NB, Danon U, Marom E, Karni A.
    Neurotherapeutics; 2021 Jul 23; 18(3):1798-1814. PubMed ID: 34159538
    [Abstract] [Full Text] [Related]

  • 15. ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis.
    Fernández-Gómez B, Marchena MA, Piñeiro D, Gómez-Martín P, Sánchez E, Laó Y, Valencia G, Nocera S, Benítez-Fernández R, Castaño-León AM, Lagares A, Hernández-Jiménez M, de Castro F.
    Br J Pharmacol; 2024 Sep 23; 181(17):3263-3281. PubMed ID: 38742374
    [Abstract] [Full Text] [Related]

  • 16. Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination.
    Harrington EP, Zhao C, Fancy SP, Kaing S, Franklin RJ, Rowitch DH.
    Ann Neurol; 2010 Nov 23; 68(5):703-16. PubMed ID: 20853437
    [Abstract] [Full Text] [Related]

  • 17. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
    Najm FJ, Madhavan M, Zaremba A, Shick E, Karl RT, Factor DC, Miller TE, Nevin ZS, Kantor C, Sargent A, Quick KL, Schlatzer DM, Tang H, Papoian R, Brimacombe KR, Shen M, Boxer MB, Jadhav A, Robinson AP, Podojil JR, Miller SD, Miller RH, Tesar PJ.
    Nature; 2015 Jun 11; 522(7555):216-20. PubMed ID: 25896324
    [Abstract] [Full Text] [Related]

  • 18. Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system.
    Zhang J, Zhang ZG, Li Y, Lu M, Zhang Y, Elias SB, Chopp M.
    Neurobiol Dis; 2016 Apr 11; 88():85-95. PubMed ID: 26805386
    [Abstract] [Full Text] [Related]

  • 19. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination.
    Hussain R, Ghoumari AM, Bielecki B, Steibel J, Boehm N, Liere P, Macklin WB, Kumar N, Habert R, Mhaouty-Kodja S, Tronche F, Sitruk-Ware R, Schumacher M, Ghandour MS.
    Brain; 2013 Jan 11; 136(Pt 1):132-46. PubMed ID: 23365095
    [Abstract] [Full Text] [Related]

  • 20. ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases.
    Pouzol L, Baumlin N, Sassi A, Tunis M, Marrie J, Vezzali E, Farine H, Mentzel U, Martinic MM.
    FASEB J; 2021 Mar 11; 35(3):e21431. PubMed ID: 33595155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.